PhRMA Kicks Off New Agenda, Including Endorsement of Drug Pricing Reforms

April 13, 2021

National lobbying group PhRMA introduced a new agenda this week with a pointed message at the White House: pharma has been instrumental in accelerating COVID-19 therapeutic efforts. It has also expressed support for drug pricing reform bills, a surprising move that is expected to reduce profits for pharmaceutical companies, but perhaps avoid larger and more substantial legislative hurdles.

“The stakes for PhRMA couldn’t be higher: House Speaker Nancy Pelosi has publicly said that she hopes portions of Democrats’ signature drug pricing bill, H.R. 3, will be included in an infrastructure bill expected to be voted on this summer. That bill would tie what the U.S. pays for certain drugs to the prices paid in other countries and threatens massive fines for drug makers that refuse to lower their prices.” Learn more here.